Search research articles
Contact Us
Filters
Showing results (21-30 of 95) with videos related to
Page
of 10
Sort By:
Therapeutic Drug Monitoring
|
July 2, 2004
Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies
C B Eap, E Jaquenoud Sirot, P Baumann
The Journal of Nervous and Mental Disease
|
January 5, 2002
Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations
P Baumann, C B Eap, D F Zullino
The American Journal of Psychiatry
|
April 3, 2001
Ondansetron for tardive dyskinesia
D F Zullino, C B Eap, P Voirol
Human Genetics
|
December 1, 1989
Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants
L Tomei, C B Eap, P Baumann, et al.
Therapeutic Drug Monitoring
|
October 1, 1996
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects
G Bertschy, C B Eap, K Powell, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
December 30, 1998
Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography
M Kosel, C B Eap, M Amey, et al.
Therapeutic Drug Monitoring
|
February 1, 1994
Probable metabolic interaction between methadone and fluvoxamine in addict patients
G Bertschy, P Baumann, C B Eap, et al.
Pharmacopsychiatry
|
April 30, 1998
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping
P Baumann, F Broly, M Kosel, et al.
Pharmacopsychiatry
|
April 5, 2012
Adherence to antidepressant treatment: what the doctor thinks and what the patient says
N Loayza, S Crettol, F Riquier, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)
|
September 25, 2010
Lack of association between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population
B Oneda, M Preisig, M Dobrinas, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 95) with videos related to
Sort By:
Page
of 10
Therapeutic Drug Monitoring
|
July 2, 2004
Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies
C B Eap, E Jaquenoud Sirot, P Baumann
The Journal of Nervous and Mental Disease
|
January 5, 2002
Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations
P Baumann, C B Eap, D F Zullino
The American Journal of Psychiatry
|
April 3, 2001
Ondansetron for tardive dyskinesia
D F Zullino, C B Eap, P Voirol
Human Genetics
|
December 1, 1989
Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants
L Tomei, C B Eap, P Baumann, et al.
Therapeutic Drug Monitoring
|
October 1, 1996
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects
G Bertschy, C B Eap, K Powell, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
December 30, 1998
Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography
M Kosel, C B Eap, M Amey, et al.
Therapeutic Drug Monitoring
|
February 1, 1994
Probable metabolic interaction between methadone and fluvoxamine in addict patients
G Bertschy, P Baumann, C B Eap, et al.
Pharmacopsychiatry
|
April 30, 1998
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping
P Baumann, F Broly, M Kosel, et al.
Pharmacopsychiatry
|
April 5, 2012
Adherence to antidepressant treatment: what the doctor thinks and what the patient says
N Loayza, S Crettol, F Riquier, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)
|
September 25, 2010
Lack of association between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population
B Oneda, M Preisig, M Dobrinas, et al.
Page
of 10